SCG101

BIOLOGICAL3 trials

Sponsors

Peking Union Medical College Hospital, SCG Cell Therapy Pte. Ltd.

Conditions

HCCHepatitis B Virus Related Hepatocellular CarcinomaHepatocellular CarcinomaHepatocellular Carcinoma Recurrent

Phase 1

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Peking Union Medical College HospitalHepatocellular Carcinoma

Start: 2021-04-14End: 2023-12-31Target: 36Updated: 2022-05-10

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

RecruitingNCT05417932

SCG Cell Therapy Pte. Ltd.Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma Recurrent

Start: 2022-10-26End: 2025-10-31Target: 46Updated: 2025-02-18

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

RecruitingNCT06617000

SCG Cell Therapy Pte. Ltd.HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma

Start: 2022-10-25End: 2025-12-31Target: 38Updated: 2024-09-27

Related Papers

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.

2025-12-054 citations

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Clinical and Molecular Hepatology2024-05-2923 citations

Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.

Journal of Clinical Oncology2023-06-011 citations